Quick Answer
Edgewise Therapeutics, Inc. reported Total Assets of $552.60 million for fiscal year 2025.
Edgewise Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $552.60M | +13.5% |
| 2024 | $486.82M | +43.2% |
| 2023 | $340.04M | -7.4% |
| 2022 | $367.10M | +28.7% |
| 2021 | $285.23M | +117.5% |
| 2020 | $131.14M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $583.47M | +14.1% | -4.9% |
| June 30, 2025 | $613.33M | +15.4% | +35.0% |
| March 31, 2025 | $454.39M | -18.0% | -6.7% |
| December 31, 2024 | $486.82M | +43.2% | -4.8% |
| September 30, 2024 | $511.28M | +64.2% | -3.8% |
| June 30, 2024 | $531.65M | +60.8% | -4.0% |
| March 31, 2024 | $553.81M | +59.9% | +62.9% |
| December 31, 2023 | $340.04M | -7.4% | +9.2% |
- Edgewise Therapeutics, Inc. showed an increase of +13.5% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Edgewise Therapeutics, Inc.’s total assets has grown by 321.4% (from $131.14 million to $552.60 million).
- The most recent figure is from Edgewise Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: